In the last trading session, 1.88 million shares of the Inozyme Pharma Inc (NASDAQ:INZY) were traded, and its beta was 1.35. Most recently the company’s share price was $1.49, and it changed around -$0.13 or -8.02% from the last close, which brings the market valuation of the company to $96.20M. INZY currently trades at a discount to its 52-week high of $6.24, offering almost -318.79% off that amount. The share price’s 52-week low was $0.72, which indicates that the current value has risen by an impressive 51.68% since then.
Inozyme Pharma Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.12. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 0 recommended INZY as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
Instantly INZY has showed a red trend with a performance of -8.02% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.8500 on recent trading dayincreased the stock’s daily price by 19.46%. The company’s shares are currently down -46.21% year-to-date, but still up 54.48% over the last five days. On the other hand, Inozyme Pharma Inc (NASDAQ:INZY) is 70.19% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $14, which translates to bulls needing to increase their stock price by 89.36% from its current value. Analyst projections state that INZY is forecast to be at a low of $14 and a high of $16.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -13.98%. Inozyme Pharma Inc earnings are expected to increase by 14.97% in 2025, but the outlook is positive 14.09% per year for the next five years.
INZY Dividends
Inozyme Pharma Inc’s next quarterly earnings report is expected to be released in June.
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, with 7.2563% or 4.49 million shares worth $20.05 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.22 shares worth $3.31 million, making up 3.44% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 1.56 shares worth around $2.32 million, which represents about 2.41% of the total shares outstanding.
